Brief: PLX Pharma Reports Q4 Loss Per Share Of $0.25

PLx Pharma Winddown

13/03/2020 11:04

March 13 (Reuters) - PLx Pharma Inc  PLXP.O :
    * . REPORTS FOURTH QUARTER 2019 RESULTS AND PROVIDES
REGULATORY
UPDATE ON VAZALORE
    * Q4 LOSS PER SHARE $0.25
    * REVENUE OF APPROXIMATELY $24,000 FOR Q4 OF 2019 COMPARED
TO $0.3
MILLION FOR Q4 OF 2018
    * PLX PHARMA -  WILL CONDUCT A BIOEQUIVALENCE STUDY FOR
VAZALORE
325 MG TO SUPPORT APPROVAL OF SNDA WHICH WILL IMPACT TIMELINE
PREVIOUSLY ANNOUNCED
    * AS OF DECEMBER 31, 2019, THE COMPANY HAD CASH AND CASH
EQUIVALENTS OF $14.0 MILLION
    * CURRENTLY HAS A MEETING WITH FDA SCHEDULED FOR END OF
APRIL
    * PLX PHARMA - $8 MILLION SERIES B PREFERRED STOCK FINANCING
SHOULD PROVIDE A CASH RUNWAY UNTIL THE END OF THE FIRST QUARTER
OF 2021
    * PLX PHARMA - COMPANY WILL NEED ADDITIONAL FINANCING UPON
SUBMISSION OF THE SNDAS
    * WILL PROVIDE AN UPDATED TIMELINE FOR VAZALORE 325 GMS ONCE
DETAILS OF STUDY DESIGN ARE CONFIRMED
    * Q4 EARNINGS PER SHARE VIEW $-0.48, REVENUE VIEW $13330.00
--
REFINITIV IBES DATA
    * PLX PHARMA -  ANNOUNCES $8 MILLION CONVERTIBLE PREFERRED
STOCK
FINANCING WITH PARK WEST AND MSD PARTNERS

Source text for Eikon:  ID:nGNX6HwQfJ 
Further company coverage:  PLXP.O 

 ((Reuters.Briefs@thomsonreuters.com;))